Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

PTK/ZK (Novartis).

Joachim Drevs¹

¹Institute of Molecular Oncology, Department of Medical Oncology, Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Germany. drevs@tumorbio.uni-freiburg.de

Idrugs : the Investigational Drugs Journal

|August 15, 2003

Summary

PTK/ZK, a novel VEGF receptor tyrosine kinase inhibitor, is being developed to inhibit angiogenesis, offering potential new treatments for various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary results.

Cancer treatment and research communications·2025

Same author

Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal Cancer.

Anticancer research·2025

Same author

Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging.

Oncology letters·2016

Same author

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014

Same author

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.

International journal of clinical pharmacology and therapeutics·2011

Same author

Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

International journal of molecular sciences·2011

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
VEGF receptor tyrosine kinases play a critical role in regulating angiogenesis.
Targeting angiogenesis is a promising strategy for cancer therapy.

Purpose of the Study:

To describe the development of PTK/ZK, a novel inhibitor targeting VEGF receptor tyrosine kinases.
To evaluate the potential of PTK/ZK as an anti-angiogenic agent for cancer treatment.

Main Methods:

PTK/ZK is a small molecule inhibitor designed to block VEGF receptor tyrosine kinase activity.
Development is being conducted by Novartis AG and Schering AG.
The compound is under investigation for its anti-angiogenic properties.

Main Results:

PTK/ZK functions as an inhibitor of VEGF receptor tyrosine kinase.
The compound is being developed for its potential to inhibit angiogenesis.
This inhibition is being explored for the treatment of various cancers.

Conclusions:

PTK/ZK demonstrates potential as an anti-angiogenic therapeutic agent.
Its development as a VEGF receptor tyrosine kinase inhibitor offers a new avenue for cancer treatment.

Related Experiment Videos